65,437 trials
Prostate Cancer
Primary: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) — 6; 0 Participants
Postoperative Nausea and Vomiting
Primary: Adherence to PONV Guidelines — 666; 5260; 5863 Participants
Pharmacokinetics of Avycaz in ICU Patients
Primary: Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients — 34 Liter
Back Pain · Osteoarthritis
Primary: Brief Pain Inventory Interference Scale — 3.7; 3.7; 3.4; 3.6 units on a scale
Pain
Primary: Pain Assessment by Visual Analog Scale at Rest — 19.08; 13.84 millimeters
Knee Osteoarthritis
Primary: Mean in Self-reported Disability Score as Measured by the Western Ontario and McMasters Universities Index Between Groups — 20.6; 20.57; 21.72 score on a scale
Long QT Syndrome
Primary: Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF) — 393; 399; 399 ms — p=0.09
Thalassemia Major With Severe Transfusional Iron Overload
Primary: Number of Participants With Improvement in Liver Iron Concentration — 3 Participants
Maple Syrup Urine Disease
Primary: 0-24 Hour AUC Leucine (Samples Collected at 0, 2, 4, 8, 12, 16, 20, and 24 Hours) — 6217; 4616 micromoles*hour/L
Smoking
Primary: Concentrations of Monohydroxybutenylmercapturic Acid (MHBMA) — 285.5; 1904 pg/mg creat — p=<0.001
HIV Infections
Primary: Neuropsychological Performance (KABC2) — 63.32; 61.13; 62.65 T scores from USA norms for this test — p=0.02
Influenza
Primary: Serum Antibody Responses — 11.76; 11.11; 47.03; 9.33 Titers — p=0.89
Malignant Peripheral Nerve Sheath Tumors · MPNST · Sarcoma
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at ≥ 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination…
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8 — 26.7; 49.2 Percentage of Participants — p==0.01
Hand Function · Stroke · Upper Extremity
Primary: Safety - Occurrence of Device-Related Adverse Events (AE) — 2; 4; 0; 1 Participants